

## 은행잎 추출물이 협심증 환자의 내피 세포 기능에 미치는 장단기 효과

배장호<sup>1</sup> · 김기식<sup>2</sup> · 이인규<sup>2</sup> · 김여희<sup>3</sup> · 김민수<sup>2</sup>  
김기영<sup>2</sup> · 남창욱<sup>2</sup> · 김윤년<sup>2</sup> · 김권배<sup>2</sup> · 정시전<sup>1</sup>

### The Short-and Long-Term Effects of Ginkgo Biloba Extracts on the Endothelial Function in Patients with Coronary Artery Disease

Jang-Ho Bae, MD<sup>1</sup>, Kee-Sik Kim, MD<sup>2</sup>, In-Kyu Lee, MD<sup>2</sup>, Yeo-Hee Kim, MD<sup>3</sup>,  
Min-Soo Kim, MD<sup>2</sup>, Ki-Young Kim, MD<sup>2</sup>, Chang-Wook Nam, MD<sup>2</sup>,  
Yoon-Nyun Kim, MD<sup>2</sup>, Kwon-Bae Kim, MD<sup>2</sup> and Shee-Juhn Chung, MD<sup>1</sup>

<sup>1</sup>Division of Cardiology, Andong Presbyterian Hospital, Andong, <sup>2</sup>Department of Internal Medicine,  
<sup>3</sup>Department of Biochemistry, School of Medicine, Keimyung University, Taegu, Korea

#### ABSTRACT

**Background** : The ginkgo biloba extracts (GBE) are known to inducing vasodilation by increasing NO or PGI<sub>2</sub>. However, the effects on the endothelial function and clinical symptoms of patients with coronary artery disease (CAD) are not clear. **Methods** : The flow-mediated endothelium-dependent brachial artery vasodilation using high-resolution ultrasound was measured before and 2 hours after intake of GBE (120 mg single PO) and 1 month after regular intake of GBE (80 mg bid PO) in 33 patients (mean ; 60 yrs, 26 males) with CAD who had been diagnosed by coronary angiogram and managed with medication for more than 1 month. **Results** : The only one patient could not continue to take GBE due to severe nausea. The frequency or severity of chest pain was decreased in 31 patients among the other 32 patients. The flow-mediated brachial artery vasodilation (mean  $\pm$ SD) were significantly ( $p < 0.001$ ) improved from  $8.9 \pm 3.9\%$  before to  $13.4 \pm 4.5\%$  and  $13.7 \pm 4.0\%$  2 hours and 1 month after taking GBE, respectively. The brachial artery diameter was increased from  $4.42 \pm 0.67$  mm before to  $4.45 \pm 0.66$  mm and  $4.64 \pm 0.60$  ( $p < 0.005$ ) after taking GBE, respectively. The endothelial function in patients with diabetes mellitus (5 from 33) was not improved 2 hours after taking GBE, but improved 1 month after GBE. The improvement of endothelial dysfunction in patients with hyperlipidemia or hypertension was less than patients without it. **Conclusion** : GBE has favorable short- and long-term effects on the endothelial function and clinical symptoms as well as long-term vasodilatation in patients with CAD without serious side effects. (Korean Circulation J 1999;29(2):919-927)

**KEY WORDS** : Ginkgo biloba extracts · Endothelial function · Coronary artery disease.

: 1999 4 26  
: 1999 9 1  
: , 700 - 712 194  
: (053) 250 - 7379 · : (053) 250 - 7434  
E - mail : kks7379@dsmc.or.kr

서 론

1960년 Lemeshow<sup>8)</sup>가 vitamin E가 4% 4% 33 1 50% 1 33 60 가 26 (79%) 33 10 (31%), 5 (15%), 가 12 (36%) 20 가 15 (75%) 4 (20%) 6)

EDRF PGI<sub>2</sub><sup>3)4)</sup> 가 5) 가

재료 및 방법

혈관 내피 세포 기능 측정

1992 Celermajer<sup>9)</sup>

대상 환자 (Table 1)

<sup>7)</sup>

vita -

Table 1. Clinical characteristics of the study population

	CAD (n=33)	Control (n=20)	P value
Age (yr)	59.6 ± 9	55.1 ± 6.7	0.058
Sex (male)	26 (79%)	15 (75%)	0.749
Hypertension	10 (31%)	0 (0%)	0.006
Diabetes	5 (15%)	0 (0%)	0.67
Smoking	12 (36%)	4 (20%)	<0.001
Cholesterol, total (mg/dl)	202 ± 36	197 ± 36	0.743
Triglyceride (mg/dl)	198 ± 142	168 ± 73	0.683
HDL-cholesterol (mg/dl)	39 ± 10	44 ± 10	0.315
LDL-cholesterol (mg/dl)	122 ± 32	123 ± 30	0.981
FBS (mg/dl)	101 ± 33	89 ± 5	0.544

CAD : coronary artery disease, HDL : high-density lipoprotein, LDL : low-density lipoprotein, FBS : fasting blood glucose

(time velocity integral) , 8 , 10 , 2

120 mg 2

300 mmHg 5

0 mmHg 1 160 mg 10

가 10

가 1

가 통계 처리

QRS 가 7) ± p 0.05

10) SPSS 7.5 chi - square, inde - pendent t - test, student paired t - test ANOVA

Hewlett - Packard Sonos 5500 7. 가

5 MHz inde - pendent t - test

가

가

가 11) 1 33 1

가 가 1 32

가 31 가

가 7) 1 가

혈관 내피 세포 기능 및 상완 동맥 내경 변화

은행잎 추출물 제제와 검사 순서 4.42 ± 0.67 mm

® ( 4.46 ± 0.59 mm

) , 24% ginkgoflavoneglycoside 가

6% terpenelacton 8.9 ± 3.9% 13.7 ± 3.2%

( $p < 0.001$ ) (Fig. 1). , , 2 1  
 $4.42 \pm 0.67$  mm,  $4.45 \pm 0.66$  mm,  $4.64 \pm 0.60$  mm  
 2  
 1 ( $p < 0.005$ ) 가가  
 (Table 2). ( $p < 0.005$ ) 가  
 $13.4 \pm 4.5\%$   $8.9 \pm 3.9\%$  동맥 경화 위험인자에 따른 내피 세포 기능 변화  
 ( $p < 0.001$ ) , 2 , 1  
 $13.7 \pm 7.3 \pm 2.8\%$ ,  $7.5 \pm 4.3\%$ ,  $11.3 \pm 1.5\%$  ,  
 $4.0\%$  ( $p < 0.001$ )  $9.2 \pm 4.0\%$ ,  $14.3 \pm 3.9\%$ ,  $14.1$   
 $\pm 4.2\%$  (Fig. 3).  
 가 (Fig. 2).  
 2 1 1  
 95% confidence interval  
 $-5.93$   $-3.18$   $-5.70$   $-3.17$  1




Fig. 1. Comparison of the baseline endothelial function between the patients with coronary artery disease and controls.

, 2 , 1  
 $6.7 \pm 4.2\%$ ,  $11.7 \pm 4.0\%$ ,  $12.1 \pm 3.3\%$  ,  
 $9.9 \pm 3.3\%$ ,  $14.2 \pm$   
 $4.7\%$ ,  $14.3 \pm 4.1\%$  (Fig. 4).  
 , ,  
 ( $p < 0.05$ )


Table 2. High-resolution ultrasonographic measurement of the study population

	Before		After 2 hours	After 1 month
	CAD n=33	Control n=20	CAD n=33	CAD n=32
Baseline				
Diameter (mm)	$4.42 \pm 0.67$	$4.46 \pm 0.59$	$4.45 \pm 0.66$	$4.64 \pm 0.60^*$
Flow (ml/min)	$225 \pm 98$	$203 \pm 98$	$225 \pm 102$	$235 \pm 90$
Hyperemic				
Diameter (mm)	$4.80 \pm 0.68$	$5.06 \pm 0.61$	$5.04 \pm 0.68$	$5.26 \pm 0.64$
Flow (ml/min)	$266 \pm 123^\ddagger$	$254 \pm 121^\ddagger$	$283 \pm 132^\ddagger$	$280 \pm 137^\ddagger$
% diameter changes	$8.9 \pm 3.9^\S$	$13.7 \pm 3.2$	$13.4 \pm 4.5$	$13.7 \pm 4.0$


CAD : coronary artery disease, Before : baseline study before taking EGB, After 2 hours : study performed 2 hours after taking EGB, After 1 month : study performed 1 month after regularly taking EGB, \* :  $p = 0.001$  compared with data performed at before or 2 hours after taking EGB in patients with CAD, † :  $p < 0.005$  compared with baseline flow, ‡ :  $p < 0.01$  compared with baseline flow, § :  $p < 0.001$  compared with controls, :  $p < 0.001$  compared with data performed at before taking EGB

200 mg/dl  
 8.4 ± 3.7%, 12.0 ± 3.9%, 12.6 ± 3.6%


9.5 ± 4.1%, 14.9 ± 4.9%, 14.8 ± 4.2%




**Fig. 2.** Serial changes of the endothelial function, expressed as percent diameter changes, after taking EGB in patients with coronary artery disease (CAD). \* : p < 0.001 compared with data performed at before taking EGB.




**Fig. 5.** Comparison of the serial endothelial function changes according to the level of serum total cholesterol. \* : p < 0.001 compared with baseline, † : p < 0.001 compared with baseline.




**Fig. 3.** Comparison of the serial endothelial function changes according to the presence of diabetes (DM). \* : p < 0.003 compared with patients without diabetes, † : p < 0.018 compared with baseline, ‡ : p < 0.001 compared with baseline.



**Fig. 6.** Comparison of the serial endothelial function changes according to the level of serum triglyceride. \* : p = 0.002 compared with hypertriglyceridemic patients, † : p < 0.046 compared with hypertriglyceridemic patients, ‡ : p < 0.001 and § : p = 0.032 compared with baseline.



**Fig. 4.** Comparison of the serial endothelial function changes according to the presence of hypertension (HBP). \* : p = 0.03 compared with patients without hypertension, † : p < 0.001 compared with baseline, ‡ : p < 0.002 compared with baseline.



**Fig. 7.** Comparison of the serial endothelial function changes according to the smoking history. \*p=0.005, † : p=0.002, ‡ : p=0.004, and § : p<0.05 compared with baseline, there were no statistical significance among any group at the same time.

32  
 200 mg/dl<sup>7)9)</sup>  
 , 2 , 1  
 7.7 ± 3.3%, 10.1 ± 4.1%, 11.9 ± 3.8%<sup>16)</sup> 가  
 , 200 mg/dl 9.7 ±  
 4.1%, 15.3 ± 3.8%, 14.9 ± 3.8% (Fig. 6). E

05) ,  
 가 (p<0.<sup>7)17)18)</sup> 가 E

2 , 1  
 9.3 ± 4.3%, 13.6 ± 3.4 %  
 13.3 ± 4.5% , 9.2%  
 ± 3.4%, 15.5 ± 4.9%, 13.6 ± 3.0% ,<sup>20)</sup>  
 1 8.5  
 ± 4.0%, 11.8 ± 5.0%, 14.0 ± 4.3% .  
 2  
 (p<0.01) 가 .

가 (Fig. 7). , 가  
 inhibitor nitrate, aspirin, ACE  
 1  
 가  
 2  
 . Dela-  
 flotte<sup>3)</sup> 가  
<sup>13)</sup> ,  
 가 가 가<sup>14)</sup> ,  
 가 가 가<sup>12)</sup> ,

(organic brain NO 가  
 syndrome)<sup>6)</sup> . 가  
 (oxidative stress)가  
 NO  
 hydroxyl radical superoxide anion  
<sup>5)</sup> NADPH - oxidase 가<sup>21)</sup> 가  
 가<sup>22)</sup>  
<sup>15)</sup> 가<sup>5)</sup> NO 가



GBE 160mg 1

가 .

결 과 :

1

가 .

32

31

50%

가 .

가 ,

GBE , 2 , 1

8.9 ± 3.9%, 13.4 ± 4.5%, 13.7 ± 4.0% GBE 2

가 가

(p<0.001) 가 ,

4.42 ± 0.67 mm, 4.45 ± 0.66 mm, 4.

64 ± 0.60 mm GBE 1

(p=0.001) .

가 ,

가

GBE

2 (7.3 ± 2.8% vs 7.5

± 4.3%) 1 (7.3 ± 2.8%

2

1

vs 11.3 ± 1.5%, p=0.018),

가 .

결 론 :

가

가 .

### 요 약

중심 단어 :

연구배경 :

(Ginkgo Biloba Extract, GBE) NO

PGI<sub>2</sub>

방 법 :

1

33

( : 60 , : 26 )

10

120 mg GBE

2

### REFERENCES

- 1) Kleijnen J, Knipschild P. *Ginkgo biloba*. *Lancet* 1992;340: 1136-9.
- 2) Peter M, Fisel J, Weisser W. *Zur pharmakologie der wirkstoffe aus ginkgo biloba*. *Drug Res* 1966;16:719-25.
- 3) Delaflotte S, Auguet M, DeFeudis FV, Baranes J, Clostre F, Drieu K, et al. *Endothelium-dependent relaxations of rabbit isolated aorta produced by carbachol and by ginkgo biloba extract*. *Biomed Biochem Acta* 1984;43:84-8.
- 4) Auguet M, Delaflotte S, Hellegouarch A, Clostre F. *The pharmacological bases for the vascular impact of ginkgo biloba extract*. In: *Funfgeld EW, editor. Rkan (ginkgo biloba)*. *Recent results in pharmacology and clinic*. 1st ed. Berlin: Springer-Verlag;1988. p.169-70.
- 5) Marcocci L, Packer L, Droy-Lefaix MT, Sekaki A, Gards-Albert M. *Antioxidant action of ginkgo biloba extract EGB 761*. *Methods Enzymol* 1994;234:462-75.
- 6) Haramaki N, Aggarwal S, Kawabata T, Droy-Lefaix MT,

- Packer L. *Effects of natural antioxidant ginkgo biloba extract (EGB 761) on myocardial ischemia-reperfusion injury. Free Radic Biol Med* 1994;16:789-94.
- 7) Bae JH, Kim KB, Kim KS, Han SW, Kim YN, Lee IK, et al. *The effect of vitamin E on the endothelial function following a single high-fat meal in normal subjects, patients with coronary heart disease and patients with diabetes. Korean Circulation J* 1998;28:1538-51.
  - 8) Lemeshow S, Hosmer DW Jr, Klar J, Lwanga SK. *Adequacy of sample size in health studies. 1st ed. Chichester: John Wiley & Sons;1990.*
  - 9) Celermajer DS, Sorenson KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, et al. *Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet* 1992;340:1111-5.
  - 10) Vogel RA, Corretti MC, Plotnick GD. *Effect of a single high-fat meal on endothelial function in healthy subjects. Am J Cardiol* 1997;79:350-4.
  - 11) Corretti MC, Plotnick GD, Vogel RA. *Technical aspects of evaluating brachial artery vasodilatation using high-frequency ultrasound. Am J Physiol* 1995;268:H1397-404.
  - 12) Iliff LD, Auer LM. *The effect of intravenous infusion of Tebonin (ginkgo biloba) on pial arteries in cats. J Neurosurg Sci* 1983;27:90-4.
  - 13) Tronnier H. *Klinisch-pharmacologische untersuchungen ber den effect eines extraktes aus ginkgo biloba L. beim postthrombotischen syndrom. Drug Res* 1968;18:551-4.
  - 14) Heiss WD, Podreka I. *Assessment of pharmacological effects on cerebral blood flow. Europ Neurol* 1978;17(Suppl 1);135-43.
  - 15) Pincemail J, Thirion A, Dupuis M, Braquet P, Drieu K, Deby C. *Ginkgo biloba extract inhibits oxygen species production generated by phorbol myristate acetate stimulated human leukocytes. Experientia* 1987;43:54-7.
  - 16) Furchgott RF, Zawadzki JV. *The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature* 1980;288:373-6.
  - 17) Treasure CB, Klein JL, Weintraub WS, Talley JD, Stillabower ME, Kosinski AS, et al. *Beneficial effect of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med* 1995;332:481-7.
  - 18) Panza JA, Quyyumi AA, Callahan TS, Epstein SE. *Effect of antihypertensive treatment on endothelium-dependent vascular relaxation in patients with essential hypertension. J Am Coll Cardiol* 1993;21:1145-51.
  - 19) Motoyama T, Kawano H, Kugiyama K, Hirashima O, Ohgushi M, Tsunoda R, et al. *Vitamin E administration improves impairment of endothelium-dependent vasodilation in patients with coronary spastic angina. J Am Coll Cardiol* 1998;32:1672-9.
  - 20) Koh KK, Bui MN, Hathaway L, Csako G, Waclawiw MA, Panza JA, et al. *Mechanism by which quinapril improves vascular function in coronary artery disease. Am J Cardiol* 1999;83:327-31.
  - 21) Halliwell B. *Free radicals, antioxidants, and human disease: Curiosity, cause, or consequence? Lancet* 1994;334:721-4.
  - 22) Tanner FC, Noll G, Boulanger CM, Luscher TF. *Oxidized low-density lipoproteins inhibit relaxations of porcine coronary arteries: Role of scavenger receptor and endothelium-derived nitric oxide. Circulation* 1991;83:2012-20.
  - 23) Joannides R, Haefeli WE, Linder L, Richard V, Bakkali EH, Thuiliez C, et al. *Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation* 1995;91:1314-9.
  - 24) Chung KF, Dent G, McCusker M, Guinot Ph, Page CP, Barnes PJ. *Effect of a ginkgolide mixture (BN 52063) in antagonising skin and platelet responses to platelet activating factor in man. Lancet* 1987;31:248-51.
  - 25) Braquet P, Hosford D. *Ethnopharmacology and the development of natural PAF antagonists as therapeutic agents. J Ethnopharmacol* 1991;32:135-9.
  - 26) Robak J, Gryglewski RJ. *Flavonoids are scavengers of superoxide anions. Biochem Pharmacol* 1988;37:837-41.
  - 27) Khaper N, Singal PK. *Effects of afterload-reducing drugs on pathogenesis of antioxidant changes and congestive heart failure in rats. J Am Coll Cardiol* 1997;29:856-61.